Okla. Stat. tit. 63, § 63-5030.3

Oklahoma Statutes - Title 63. Public Health and Safety Page 1734

A. The Medicaid Drug Utilization Review Board shall have the

power and duty to:

1. Advise and make recommendations regarding rules promulgated

by the Oklahoma Health Care Authority Board to implement the

provisions of this act;

2. Oversee the development, implementation and assessment of a

Medicaid retrospective and prospective drug utilization review

program, including making recommendations regarding contractual

agreements of the Oklahoma Health Care Authority with any entity

involved in processing and reviewing Medicaid drug profiles for the

drug utilization review program in accordance with the provisions of

this act;

3. Develop and apply the criteria and standards to be used in

retrospective and prospective drug utilization review. The criteria

and standards shall be based on the compendia and federal Food and

Drug Act approved labeling, and shall be developed with professional

input;

4. Provide a period for public comment on each meeting agenda.

As necessary, the Medicaid Drug Utilization Review Board may include

a public hearing as part of a meeting agenda to solicit public

comment regarding proposed changes in the prior authorization

program and the retrospective and prospective drug utilization

review processes. Notice of proposed changes to the prior

authorization status of a drug or drugs shall be included in the

monthly meeting agenda at least thirty (30) days prior to the

consideration or recommendation of any proposed changes in prior

authorization by the Medicaid Drug Utilization Review Board;

5. Establish provisions to timely reassess and, as necessary,

revise the retrospective and prospective drug utilization review

process;

6. Make recommendations regarding the prior authorization of

prescription drugs pursuant to the provisions of Section 5 of this

act; and

7. Provide members of the provider community with educational

opportunities related to the clinical appropriateness of

prescription drugs.

B. Any party aggrieved by a decision of the Oklahoma Health

Care Authority Board or the Administrator of the Oklahoma Health

Care Authority, pursuant to a recommendation of the Medicaid Drug

Utilization Review Board, shall be entitled to an administrative

hearing before the Oklahoma Health Care Authority Board pursuant to

the provisions of the Administrative Procedures Act.